In spite of differences in etiology, RA and OA lead to astonishingly similar synovitic alterations. Fibroblastic transformation of the synovial membrane and an increase in monocytes constitute a rare but highly characteristic feature of RA. Monocytes synthesize factor (F) XIII, implying that FXIII (a and s) in synovial tissue might help to differentiate between RA and OA. Biopsies were obtained at open surgery from 98 unselected patients with the clinical diagnosis of RA (n = 54) or OA (n = 44). In a three-stage (ABC) immunoperoxidase technique, polyclonal antisera against factor XIIIa and factor XIIIs were investigated. Compared to OA sections. RA synovium showed more FXIIIa-positive cells-monocytes, fibrocytes, fibroblasts and synovial lining cells. In the subsynovial layer, band-like structure of FXIIIa-stained cells was observed in 27.8% of the RA patients, but in only one OA specimen. Higher proportions of FXIIIa-positive monocytes, macrophages, histiocytes and fibroblasts, as well as positive Langhans giant cells and vascular wall regions (except endothelial cells), were observed in RA. OA specimens revealed more intense FXIIIa labeling of these cells with a lower percentage of stained cells. Overall, labeling with FXIIIs antibody resulted in less intense staining. In conclusion, distinction between synovitis caused by RA and synovitis due to OA is possible, as the former show higher numbers of FXIIIa-positive cells, including monocytes, fibroblasts, fibrocytes and synovial lining cells. Further more, RA tissue is stained less intensely than OA tissue. There is evidence for continuous excretion of FXIII in the synovial membrane by the above-mentioned cell systems.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF01419952DOI Listing

Publication Analysis

Top Keywords

factor xiiia
8
xiiia factor
8
factor xiiis
8
synovial membrane
8
fxiii synovial
8
synovial lining
8
cells
8
lining cells
8
cells observed
8
synovial
6

Similar Publications

Background: Neutrophil Extracellular Traps can contribute to thrombosis via stabilization fibrin network, which is normally conducted by plasma transglutaminase, Factor XIII-A as part of coagulation cascade. The possible presence and activity of FXIII-A in neutrophils or during NETosis is unknown. Here, we investigated potential presence of FXIII-A in neutrophils and participation in NET-fibrinogen interaction.

View Article and Find Full Text PDF

There is an interaction between dendrocytes and mast cells in the skin. However, in elastosis-related diseases such as actinic cheilitis (AC) and lower lip squamous cell carcinoma (LLSCC), this interaction remains unknown. We investigated the presence of intact and degranulated mast cells in AC and LLSCC.

View Article and Find Full Text PDF
Article Synopsis
  • - FXIII-A deficiency is a rare bleeding disorder linked to serious complications like brain hemorrhages and miscarriages, with a higher prevalence of a milder form (heterozygous deficiency) found in up to 3.5% of the population.
  • - Individuals with severe FXIII-A deficiency require consistent preventative treatment, while heterozygous individuals, especially women, may only need treatment during specific bleeding events.
  • - Personalized treatment strategies based on individual patient factors (e.g., age, weight, and clinical situation) are essential for optimizing the effectiveness of therapy for FXIII deficiencies.
View Article and Find Full Text PDF

Myositis ossificans is a benign ossifying nodule that can affect any type of tissue but is most commonly found in muscle. Occurrence in the soft tissue of the subcutis is less common and has been referred to as panniculitis ossificans. In this case report, we describe a 46-year-old woman who presented with a 1.

View Article and Find Full Text PDF

The third-generation anticoagulants: factors XI, XII, and XIII inhibitors.

Egypt Heart J

October 2024

Department of Cardiology, King George's Medical University, Shahmina Road, Chowk, Lucknow, Uttar Pradesh, 226003, India.

Article Synopsis
  • * Factor XI inhibitors have shown better efficacy and safety compared to enoxaparin in reducing venous thromboembolic incidents, while factor XII inhibitors could also lower bleeding risks based on preliminary animal research.
  • * Further large-scale human studies are needed to confirm the effectiveness of factor XI, XII, and XIII inhibitors in preventing thromboembolic events, as the early results for factors XII and XIII still require validation.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!